A new guideline from AAN offers recommendations on the use of behavioral, nutraceutical, and complementary and alternative medicine (CAM) for improving sleep disorders in children with ASD.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.
The researchers analyzed data from 1649 combat-exposed United States military veterans who were evaluated at a Veterans Affairs facility between 2009 and 2012 after deployment to the wars in Iraq and/or Afghanistan.
The FDA has approved lemborexant for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
Postmenopausal women more often have sleep-onset insomnia disorder and are more likely to screen positive for obstructive sleep apnea.
The researchers found that adults with ASD showed significant impairments in both objective and subjective measures of sleep compared with controls.
The key findings of the study, conducted in the world’s largest BD cohort with genotypic and phenotypic data, offer potential sleep-related genetic underpinnings for BD diagnostic groups.
Individual and coexisting symptoms of insomnia are associated with increased risk for cardio-cerebral vascular diseases.
Cognitive behavioral therapy (CBT) may reduce the incidence of insomnia symptoms in adolescents, according to study data presented at the 2019 World Sleep Congress.
Investigators sought to determine the mental health needs of evacuees of devastating wildfires in Canada and to distribute evidence-based tools to promote resilience.
